$RPHM
Reneo Pharmaceuticals Inc

2022 Q4 Form 10-Q Financial Statement

#000095017022023250 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.205M $3.902M $3.434M
YoY Change 19.32% 13.63% 412.54%
% of Gross Profit
Research & Development $10.36M $9.938M $9.318M
YoY Change 45.87% 6.65% 110.29%
% of Gross Profit
Depreciation & Amortization $25.00K $22.00K $13.00K
YoY Change 47.06% 69.23% 44.44%
% of Gross Profit
Operating Expenses $14.56M $13.84M $12.75M
YoY Change 37.07% 8.53% 150.09%
Operating Profit -$13.84M -$12.75M
YoY Change 8.53% 150.09%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $962.0K $833.0K $17.00K
YoY Change 5558.82% 4800.0% 70.0%
Pretax Income -$13.60M -$13.01M -$12.74M
YoY Change 28.22% 2.14% 150.2%
Income Tax
% Of Pretax Income
Net Earnings -$13.60M -$13.01M -$12.74M
YoY Change 28.22% 2.14% 150.0%
Net Earnings / Revenue
Basic Earnings Per Share -$0.53 -$0.52
Diluted Earnings Per Share -$0.55 -$0.53 -$522.0K
COMMON SHARES
Basic Shares Outstanding 24.53M 24.50M 24.41M
Diluted Shares Outstanding 24.50M 24.40M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $101.2M $116.1M $157.7M
YoY Change -31.49% -26.41%
Cash & Equivalents $19.93M $62.13M $126.4M
Short-Term Investments $81.25M $53.95M $31.33M
Other Short-Term Assets $5.180M $4.918M $4.931M
YoY Change -14.58% -0.26%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $106.4M $121.0M $162.7M
YoY Change -30.82% -25.62%
LONG-TERM ASSETS
Property, Plant & Equipment $453.0K $241.0K $200.0K
YoY Change 113.68% 20.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $84.00K $79.00K $78.00K
YoY Change 7.69% 1.28%
Total Long-Term Assets $1.829M $1.506M $278.0K
YoY Change 530.69% 441.73%
TOTAL ASSETS
Total Short-Term Assets $106.4M $121.0M $162.7M
Total Long-Term Assets $1.829M $1.506M $278.0K
Total Assets $108.2M $122.5M $162.9M
YoY Change -29.76% -24.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.893M $2.189M $1.271M
YoY Change -6.38% 72.23%
Accrued Expenses $4.827M $6.851M $5.082M
YoY Change 15.48% 34.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.124M $9.450M $6.353M
YoY Change 14.87% 48.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.088M $1.009M $382.0K
YoY Change 551.5% 164.14%
Total Long-Term Liabilities $1.088M $1.009M $382.0K
YoY Change 551.5% 164.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.124M $9.450M $6.353M
Total Long-Term Liabilities $1.088M $1.009M $382.0K
Total Liabilities $8.212M $10.46M $6.735M
YoY Change 20.53% 55.29%
SHAREHOLDERS EQUITY
Retained Earnings -$136.7M -$123.1M -$74.10M
YoY Change 61.34% 66.13%
Common Stock $3.000K $3.000K $3.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $99.97M $112.0M $156.2M
YoY Change
Total Liabilities & Shareholders Equity $108.2M $122.5M $162.9M
YoY Change -29.76% -24.82%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$13.60M -$13.01M -$12.74M
YoY Change 28.22% 2.14% 150.0%
Depreciation, Depletion And Amortization $25.00K $22.00K $13.00K
YoY Change 47.06% 69.23% 44.44%
Cash From Operating Activities -$15.61M -$10.79M -$9.672M
YoY Change 55.8% 11.6% 68.21%
INVESTING ACTIVITIES
Capital Expenditures $250.0K -$28.00K -$77.00K
YoY Change -377.78% -63.64% -870.0%
Acquisitions
YoY Change
Other Investing Activities -$26.67M -$45.41M -$4.432M
YoY Change -423.51% 924.53% -469.33%
Cash From Investing Activities -$26.92M -$45.44M -$4.509M
YoY Change -430.15% 907.65% -478.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 325.0K 97.00K 222.0K
YoY Change 173.11% -56.31% 344.0%
NET CHANGE
Cash From Operating Activities -15.61M -10.79M -9.672M
Cash From Investing Activities -26.92M -45.44M -4.509M
Cash From Financing Activities 325.0K 97.00K 222.0K
Net Change In Cash -42.20M -56.13M -13.96M
YoY Change 2313.09% 302.12% 209.51%
FREE CASH FLOW
Cash From Operating Activities -$15.61M -$10.79M -$9.672M
Capital Expenditures $250.0K -$28.00K -$77.00K
Free Cash Flow -$15.86M -$10.77M -$9.595M
YoY Change 59.73% 12.2% 66.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2235
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001637715
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40315
dei Entity Registrant Name
EntityRegistrantName
Reneo Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2309515
dei Entity Address Address Line1
EntityAddressAddressLine1
18575 Jamboree Road, Suite 275-S
dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92612
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
283-0280
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
RPHM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24529646
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62132000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124660000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
53948000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
23010000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4918000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6064000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
120998000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
153734000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
241000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
212000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1186000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
79000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
78000
CY2022Q3 us-gaap Assets
Assets
122504000
CY2021Q4 us-gaap Assets
Assets
154024000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24455390
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2189000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2022000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6851000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4180000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
410000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9450000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6202000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
943000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
167000
CY2022Q3 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
66000
CY2021Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
444000
CY2022Q3 us-gaap Liabilities
Liabilities
10459000
CY2021Q4 us-gaap Liabilities
Liabilities
6813000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24529646
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24529646
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24457838
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
235151000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
231902000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123083000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84728000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-26000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
34000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
112045000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
147211000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
122504000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
154024000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9938000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9318000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27348000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21069000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3902000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3434000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11938000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8125000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
13840000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
12752000
us-gaap Operating Expenses
OperatingExpenses
39286000
us-gaap Operating Expenses
OperatingExpenses
29194000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13840000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12752000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39286000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29194000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
833000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
471000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
56000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
931000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13007000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12735000
us-gaap Net Income Loss
NetIncomeLoss
-38355000
us-gaap Net Income Loss
NetIncomeLoss
-29163000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-194000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
12000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-60000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
17000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13201000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12723000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38415000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29146000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.82
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24496313
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24496313
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24396798
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24396798
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24472974
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24472974
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16025813
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16025813
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
147211000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1107000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
30000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13036000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
135318000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1006000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
41000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
104000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12312000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
124157000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
990000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
99000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-194000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13007000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
112045000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-42115000
CY2021Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
70663
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
139000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
169000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-113000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7212000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-48717000
CY2021Q2 rphm Convertible Preferred Stock Value Issued Upon Conversion
ConvertiblePreferredStockValueIssuedUponConversion
140078000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
84533000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
854000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
14000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9216000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
167551000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1145000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
235000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
12000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12735000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
156208000
us-gaap Net Income Loss
NetIncomeLoss
-38355000
us-gaap Net Income Loss
NetIncomeLoss
-29163000
us-gaap Share Based Compensation
ShareBasedCompensation
3103000
us-gaap Share Based Compensation
ShareBasedCompensation
2470000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
63000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
33000
rphm Fair Value Changes Of Share Based Performance Award
FairValueChangesOfShareBasedPerformanceAward
-378000
rphm Fair Value Changes Of Share Based Performance Award
FairValueChangesOfShareBasedPerformanceAward
284000
rphm Operating Lease Right Of Use Asset Amortization Expense Lease Modification And Impairment
OperatingLeaseRightOfUseAssetAmortizationExpenseLeaseModificationAndImpairment
-338000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1146000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3577000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2838000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1816000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-338000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
62000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31749000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27962000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
96000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
108000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
67329000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
31421000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
36500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30925000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31529000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
84641000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
146000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
407000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
146000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
132287000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-62528000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
72796000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124660000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53613000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62132000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
126409000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1524000
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On April 5, 2021, in connection with the IPO, the Company effected a 1-for-4.4748 reverse stock split of its common stock. The par value and the authorized number of shares of the common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the Series A and Series B convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented.
rphm Vesting Of Unvested Exercised Options
VestingOfUnvestedExercisedOptions
19000
CY2022Q3 rphm Cash And Cash Equivalents At Carrying Value And Short Term Investments
CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments
116100000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4779620
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3215904
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q3 rphm Accrued Clinical And Regulatory Expenses
AccruedClinicalAndRegulatoryExpenses
1955000
CY2021Q4 rphm Accrued Clinical And Regulatory Expenses
AccruedClinicalAndRegulatoryExpenses
1236000
CY2022Q3 rphm Accrued Manufacturing Expense
AccruedManufacturingExpense
2088000
CY2021Q4 rphm Accrued Manufacturing Expense
AccruedManufacturingExpense
1482000
CY2022Q3 rphm Accrued Compensation Expense
AccruedCompensationExpense
2287000
CY2021Q4 rphm Accrued Compensation Expense
AccruedCompensationExpense
1027000
CY2022Q3 rphm Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
521000
CY2021Q4 rphm Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
435000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6851000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4180000
us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
us-gaap Lease Practical Expedient Use Of Hindsight
LeasePracticalExpedientUseOfHindsight
true
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
400000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
285000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1486000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
133000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1353000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
132000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
414000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
323000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
332000
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7215505
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4215643
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.49
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13530000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
555576
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.36
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
50712
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
250387
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.09
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4470120
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.36
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
729000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1991029
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
5.02
rphm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P6Y4M24D
rphm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue
479000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2898534
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
479000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.031
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.025
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.007
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.936
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.907
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.872
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.729
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
990000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1145000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3103000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2470000

Files In Submission

Name View Source Status
rphm-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-22-023250-index-headers.html Edgar Link pending
0000950170-22-023250-index.html Edgar Link pending
0000950170-22-023250.txt Edgar Link pending
0000950170-22-023250-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img1365250_0.jpg Edgar Link pending
img26607342_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rphm-20220930.htm Edgar Link pending
rphm-20220930.xsd Edgar Link pending
rphm-ex10_2.htm Edgar Link pending
rphm-ex31_1.htm Edgar Link pending
rphm-ex31_2.htm Edgar Link pending
rphm-ex32_1.htm Edgar Link pending
rphm-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rphm-20220930_pre.xml Edgar Link unprocessable
rphm-20220930_def.xml Edgar Link unprocessable
rphm-20220930_lab.xml Edgar Link unprocessable
rphm-20220930_htm.xml Edgar Link completed